stoxline Quote Chart Rank Option Currency Glossary
Statera Biopharma, Inc. (STAB)
0.0007  0 (16.67%)    04-19 15:26
Open: 0.0006
High: 0.0007
Volume: 25,176
Pre. Close: 0.0006
Low: 0.0006
Market Cap: 0(M)
Technical analysis
2023-05-19 4:49:48 PM
Short term     
Mid term     
Targets 6-month :  0.02 1-year :  0.03
Resists First :  0.02 Second :  0.02
Pivot price 0.02
Supports First :  0.01 Second :  0.01
MAs MA(5) :  0.02 MA(20) :  0.02
MA(100) :  0.03 MA(250) :  0.12
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  41.5 D(3) :  37.3
RSI RSI(14): 48.2
52-week High :  0.31 Low :  0.01
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ STAB ] has closed above bottom band by 32.9%. Bollinger Bands are 82.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 74 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.02 - 0.02 0.02 - 0.02
Low: 0.02 - 0.02 0.02 - 0.02
Close: 0.02 - 0.02 0.02 - 0.02
Company Description

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. The company is based in Fort Collins, Colorado.

Headline News

Wed, 15 Mar 2023
Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs - Yahoo Finance

Thu, 06 Oct 2022
What Is Going on With Statera (STAB) Stock Today? - InvestorPlace

Sun, 11 Sep 2022
Statera Biopharma faces involuntary bankruptcy petition - Loveland Reporter-Herald

Wed, 13 Apr 2022
Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod ... - PR Newswire

Mon, 13 Sep 2021
STAB News Today | Why did Statera Biopharma stock go up today? - MarketBeat

Mon, 13 Sep 2021
Statera Biopharma (STAB) Stock Price, News & Analysis - MarketBeat

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 71 (M)
Shares Float 48 (M)
Held by Insiders 12.1 (%)
Held by Institutions 3.4 (%)
Shares Short 775 (K)
Shares Short P.Month 829 (K)
Stock Financials
EPS -2.48
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.21
Profit Margin 0 %
Operating Margin -573.3 %
Return on Assets (ttm) -23.9 %
Return on Equity (ttm) -287 %
Qtrly Rev. Growth 183.5 %
Gross Profit (p.s.) 0.01
Sales Per Share 0.05
EBITDA (p.s.) -0.29
Qtrly Earnings Growth 0 %
Operating Cash Flow -12 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value -0.1
Price to Sales 0.38
Price to Cash Flow -0.12
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android